Clinical trials
Major Depressive Disorder trials in Poland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
82 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2005 | 2 |
| 2006 | 4 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 5 |
| 2011 | 4 |
| 2012 | 4 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 5 |
| 2020 | 5 |
| 2021 | 4 |
| 2022 | 6 |
| 2023 | 5 |
| 2024 | 3 |
| 2025 | 11 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 54 |
| Terminated | 11 |
| Recruiting | 10 |
| Enrolling by invitation | 3 |
| Active, not recruiting | 2 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Janssen Research & Development, LLC | 12 |
| H. Lundbeck A/S | 7 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 6 |
| Eli Lilly and Company | 4 |
| Takeda | 4 |
| AstraZeneca | 3 |
| GlaxoSmithKline | 3 |
| Medical University of Gdansk | 3 |
| Neurocrine Biosciences | 3 |
| Cybin IRL Limited | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Major Depressive Disorder | 82 |
| Depressive Disorder | 16 |
| Mood Disorders | 11 |
| Mental Disorders | 8 |
| Depressive Disorder, Treatment-Resistant | 6 |
| Anhedonia | 4 |
| Anxiety Disorders | 3 |
| Bipolar Disorder | 1 |
| Dementia | 1 |
| Dissociative Disorders | 1 |
Trials
Showing 51 to 75 of 82. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.